Martin Voss, MD, reviews data updates from ASCO GU 2024 on the KEYNOTE-B61 study of lenvatinib + pembrolizumab in nccRCC in addition to real-world outcomes in patients with chromophobe RCC.
FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC
The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.
A Sneak Peek at 2025 ASCO From the GU Perspective
Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.
CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer
The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.
Finding Ways to Break the Mold in GU Oncology
Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.
ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC
Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.
FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma
Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.